Breast Cancer Reagents

Breast Cancer Research Reagents — HER2, ER, PR, TROP2 | abinScience

Breast cancer is the most commonly diagnosed cancer globally. Molecular subtyping — Luminal A/B, HER2-enriched, and triple-negative (TNBC) — dictates treatment strategy and prognosis. abinScience offers validated reagents targeting HER2/ErbB2, ER, PR, BRCA, Ki-67, TROP2, Nectin-4, and emerging ADC targets for breast cancer biomarker discovery and translational research. RUO

Key Biomarkers & Targets

HER2 / ErbB2

CD340 / ERBB2

Overexpressed in ~20% of breast cancers. Therapeutic target for trastuzumab, pertuzumab, T-DXd. 100+ antibodies and biosimilar-grade proteins.

Antibodies • Proteins • Biosimilars

ERα / ESR1

Estrogen Receptor alpha

Expressed in ~75% of breast cancers; primary determinant for endocrine therapy eligibility. Antibodies with IHC validation available.

Antibodies

PR / PGR

Progesterone Receptor

Co-assessed with ER for luminal subtype classification. Antibodies available for research use.

Antibodies

TROP2

TACSTD2

Overexpressed in TNBC; validated ADC target (sacituzumab govitecan). 29 antibodies and recombinant proteins for ADC target research.

Antibodies • Proteins • Biosimilars

Nectin-4

PVRL4

Emerging ADC target in breast and urothelial cancers (enfortumab vedotin). 21 detection antibodies and recombinant proteins.

Antibodies • Proteins

Ki-67 / MKI67

Proliferation Marker

Distinguishes Luminal A (low Ki-67) from Luminal B (high Ki-67). Antibodies available for research use.

Antibodies

Why Researchers Choose abinScience for Breast Cancer

Full Subtyping Panel ER, PR, HER2, Ki-67 antibodies for the four-marker IHC panel used in clinical breast cancer molecular classification.

ADC Target Profiling TROP2, Nectin-4, HER2, and emerging targets (HER3, FRα, CDH6) — recombinant proteins and antibodies for antibody–drug conjugate discovery.

TNBC Immune Microenvironment PD-L1, CTLA-4, and TIL-associated markers for characterizing the immunosuppressive tumor microenvironment in triple-negative breast cancer.

Biosimilar Comparability Research-grade trastuzumab, pertuzumab, and T-DXd reference proteins for biosimilar analytical similarity and potency testing.

Original Manufacturer Pricing Direct-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

Molecular subtyping by IHC: Classify breast tumors as Luminal A, Luminal B, HER2-enriched, or TNBC using our ER/PR/HER2/Ki-67 antibody panel on FFPE tissue sections.
HER2-targeted therapy development: Research-grade HER2 biosimilar proteins available with ELISA, FACS, and Functional assay validation for comparability studies.
ADC target validation: Anti-TROP2 antibodies with FCM validation and anti-Nectin-4 antibodies with FCM/ELISA validation available for ADC target expression profiling.
CDK4/6 pathway analysis: CDK4, CDK6, and related pathway antibodies available for studying resistance mechanisms to CDK4/6 inhibitors in ER+ breast cancer.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Which antibodies are recommended for HER2 IHC scoring?

Yes — clone 1A064 with ELISA, IHC, and WB validation (Human). Research-grade HER2 biosimilar proteins (e.g., disitamab, trastuzumab) also available. Research use only.

Do you carry ER/ESR1 antibodies?

Yes. Anti-ESR1/ERα polyclonal antibodies with ELISA, IHC, and WB validation (Human/Mouse/Rat). Monoclonal clones (e.g., RB125) with ELISA and IF validation also available.

What reagents do you recommend for TNBC research?

For TNBC, we offer: PD-L1 antibodies (IHC/WB/FC validated), TROP2 antibodies (FC validated), Nectin-4 antibodies (FC/ELISA validated), CTLA-4 antibodies (IHC/WB validated), and EGFR antibodies (IHC/WB validated).

Can I use your TROP2 antibodies for ADC target expression research studies?

Anti-TROP2/TACSTD2 monoclonal antibodies with FC validation (e.g., clones TP15-4, SAA0113). Research-grade biosimilar proteins (sacituzumab, datopotamab) and recombinant TROP2 proteins (His/Fc-tagged) also available.

Do you offer custom antibody development for novel breast cancer targets?

Yes — our parent company AtaGenix provides full custom antibody services from immunogen design through hybridoma production, including targets not yet in our catalog.